Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug-Target Mendelian Randomization Study.

Key Points

• The research aims to evaluate the effect of metformin targets on colorectal cancer outcomes through genetic analysis.
• Utilized a Mendelian randomization approach to establish causal relationships
• Focused on the genetic target ampkγ1 (prkag1)
• Assessed the impact of metformin on colorectal cancer prevention
• Evidence suggests a protective role of metformin against colorectal cancer through ampkγ1
• Supports the need for randomized controlled trials to further investigate metformin's efficacy